Evidence map›Paper›PMID 35353881›Full record

ArticleCarcinogenesis2022

Suppressing the activation of protein kinase A as a DNA damage-independent mechanistic lead for dihydromethysticin prophylaxis of NNK-induced lung carcinogenesis.

Tengfei Bian, Haocheng Ding, Yuzhi Wang, Qi Hu, Sixue Chen, Naomi Fujioka, F Zahra Aly, Junxuan Lu, Zhiguang Huo, Chengguo Xing

Open access · greenAbstract read
In one paragraph

Article in Carcinogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Opportunities and Challenges of Kava in Lung Cancer Prevention.International journal of molecular sciences · 2023
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Tengfei BianDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Haocheng DingDepartment of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA.
Yuzhi WangDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Qi HuDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Sixue ChenProteomics and Mass Spectrometry, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-6690-7612
Naomi FujiokaDepartment of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.
F Zahra AlyDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, 1345 Center Drive, Gainesville, FL, USA.
Junxuan LuDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Zhiguang HuoDepartment of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-8032-4392
Chengguo XingDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-4266-6236
University of Florida · USPennsylvania State University · USUniversity of Minnesota Medical Center · US

Funding

Dihydromethysticin (DHM) for Lung Cancer ChemopreventionR01CA193278 · NCI · UNIVERSITY OF MINNESOTA · PI XING, CHENGGUO · 2015 to 2019
$1.7M
NCI NIH HHS R01 CA193278
6 · The paper itself

Abstract

Our earlier work demonstrated varying potency of dihydromethysticin (DHM) as the active kava phytochemical for prophylaxis of tobacco carcinogen nicotine-derived nitrosamine ketone (NNK)-induced mouse lung carcinogenesis. Efficacy was dependent on timing of DHM gavage ahead of NNK insult. In addition to DNA adducts in the lung tissues mitigated by DHM in a time-dependent manner, our in vivo data strongly implicated the existence of DNA damage-independent mechanism(s) in NNK-induced lung carcinogenesis targeted by DHM to fully exert its anti-initiation efficacy. In the present work, RNA seq transcriptomic profiling of NNK-exposed (2 h) lung tissues with/without a DHM (8 h) pretreatment revealed a snap shot of canonical acute phase tissue damage and stress response signaling pathways as well as an activation of protein kinase A (PKA) pathway induced by NNK and the restraining effects of DHM. The activation of the PKA pathway by NNK active metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) at a concentration incapable of promoting DNA adduct was confirmed in a lung cancer cell culture model, potentially through NNAL binding to and activation of the β-adrenergic receptor. Our in vitro and in vivo data overall support the hypothesis that DHM suppresses PKA activation as a key DNA damage-independent mechanistic lead, contributing to its effective prophylaxis of NNK-induced lung carcinogenesis. Systems biology approaches with a detailed temporal dissection of timing of DHM intake versus NNK exposure are warranted to fill the knowledge gaps concerning the DNA damage-driven mechanisms and DNA damage-independent mechanisms to optimize the implementation strategy for DHM to achieve maximal lung cancer chemoprevention.

Indexed as

Lung NeoplasmsNitrosaminesAnimalsCarcinogenesisCarcinogensCyclic AMP-Dependent Protein KinasesDNA AdductsDNA DamageLungMicePyrones7,8-dihydromethysticinCarcinogensCyclic AMP-Dependent Protein KinasesDNA AdductsNitrosaminesPyrones

Identifiers

PMID35353881
PMCPMC9653071
OpenAlexW4221093224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.